大剂量丙种球蛋白预防毛细支气管炎发展成哮喘的疗效观察

Clinical Effect of High Dose Intravenous Immunoglobulin on Prevention of Bronchiolitis Developing into Asthma

目的:探讨大剂量丙种球蛋白静脉滴注预防毛细支气管炎发展成哮喘的临床疗效。方法:毛细支气管炎患儿158例随机分为观察组和对照组各79例。对照组给予抗感染、止咳平喘等常规治疗,观察组在此基础上加用丙种球蛋白1.0 g·kg^(-1)·d^(-1),ivd,连用2 d后,观察并比较两组患儿主要症状消失时间、住院时间、有效率及不良反应发生率;随访1年后观察两组哮喘发生率。结果:观察组总有效率为96.2%,显著高于对照组77.2%(P<0.05)。观察组患儿气促消失时间、肺部啰音消失时间以及住院时间均明显短于对照组(P<0.05)。随访1年后观察组患儿哮喘发生率显著低于对照组(P<0.05)。两组患儿药品不良反应差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,加用大剂量静脉丙种球蛋白对预防毛细支气管炎发展成为哮喘具有明显的预防作用,值得推广应用。

Objective： To study the curative effect of high dose intravenous immunoglobulin on the prevention of bronchiolitis developing into asthma. Methods： 158 cases of children with bronchiolitis were randomly divided into observation group and control group,79 cases in each group. The control group was given routine treatment of anti infection,cough and asthma,the observation group was given intravenous injection of gamma globulin protein 1. 0 g·kg-1·d- 1 additionally,on the basis of the control group. After 2d’s treatmen,the main symptoms disappeared time,hospitalization time,efficiency and adverse reaction rate of the two groups were observed and compared,and the incidence of asthma of the two groups after 1 year’s follow-up were observed. Results： After treatment,the total effective rate of the observation group was96. 2%,significantly higher than that of the control group（ 77. 2%,P 〈 0. 05）. The dyspnea disappearance time,pulmonary rales disappeared time and hospitalization time of observation group were significantly shorter than the control group（ P 〈0. 05）. After the follow-up period,the incidence of asthma in the observation group was significantly lower than that in the control group（ P 〈 0. 05）. There was no significant difference in adverse drug reactions between the two groups（ P 〉0. 05）. Conclusion： Useing high dose intravenous immunoglobulin on the basis of conventional therapy on prevention of bronchiolitis developing as an asthma,it has significant preventive effect,is worth popularization and application.